Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$119.15 USD
+0.15 (0.13%)
Updated Sep 6, 2024 03:59 PM ET
After-Market: $119.16 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
ASND 119.15 +0.15(0.13%)
Will ASND be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ASND based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ASND
Ascendis (ASND) Up on FDA Nod for Hormone Therapy Yorvipath
Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains?
ASND: What are Zacks experts saying now?
Zacks Private Portfolio Services
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
Other News for ASND
Biotech Alert: Searches spiking for these stocks today
Ascendis Pharma Takes A Big Price Cut On Skytrofa
Biotech Alert: Searches spiking for these stocks today
Dollar Tree downgraded, Roku upgraded: Wall Street's top analyst calls
Ascendis Pharma just upgraded at Oppenheimer, here's why